Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa/carbidopa/entacapone (Stalevo).

Robert A Hauser1

  • 1Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA.

Neurology
|January 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor.

Parkinsonism & related disorders·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology·2026
Same author

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real-World Early Experience Program.

Movement disorders clinical practice·2026
Same author

LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease.

Clinical parkinsonism & related disorders·2025
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Stalevo, a new combination pill for Parkinson's disease (PD), offers a simpler treatment option. It combines levodopa/carbidopa/entacapone into one dose, improving convenience for patients experiencing "wearing-off" symptoms.

Area of Science:

  • Neurology
  • Pharmacology
  • Pharmaceutical Sciences

Background:

  • Idiopathic Parkinson's disease (PD) is a progressive neurodegenerative disorder.
  • End-of-dose "wearing-off" is a common complication of levodopa therapy in PD patients.
  • Current treatment often involves multiple medications, posing challenges for patient adherence and convenience.

Purpose of the Study:

  • To introduce and evaluate the Stalevo (levodopa/carbidopa/entacapone) combination product for Parkinson's disease management.
  • To assess the pharmacokinetic profile and bioequivalence of Stalevo compared to separate formulations.
  • To highlight the clinical advantages and switching strategies for Stalevo in PD patients.

Main Methods:

  • Pharmacokinetic studies were conducted to demonstrate bioequivalence.

Related Experiment Videos

  • Clinical advantages were assessed based on patient convenience and medication regimen simplification.
  • Switching guidelines were proposed for different levodopa/carbidopa formulations (immediate-release and controlled-release).

    • Main Results:

    • Stalevo demonstrated bioequivalence to corresponding doses of levodopa/carbidopa plus entacapone.
    • The combination product offers a single-pill option, reducing the number of tablets patients need to take.
    • Stalevo 50 and 100 offer smaller tablet sizes compared to entacapone alone, aiding patients with swallowing difficulties.
    • Direct switching to Stalevo is feasible for most PD patients on levodopa/carbidopa immediate-release plus entacapone.
    • Switching patients on levodopa/carbidopa controlled-release requires consideration of differing levodopa bioavailability.

    Conclusions:

    • Stalevo provides a clinically advantageous, convenient, and potentially more manageable treatment option for Parkinson's disease patients experiencing end-of-dose wearing-off.
    • The single-pill formulation simplifies medication regimens, particularly benefiting patients with complex schedules or swallowing issues.
    • Appropriate switching strategies should be employed based on the patient's current levodopa/carbidopa formulation to ensure optimal therapeutic outcomes.